1. Home
  2. GOVX

as 11-14-2024 12:34pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Founded: 2001 Country:
United States
United States
Employees: N/A City: SMYRNA
Market Cap: 17.1M IPO Year: N/A
Target Price: $14.20 AVG Volume (30 days): 3.6M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -7.44 EPS Growth: N/A
52 Week Low/High: $1.09 - $11.18 Next Earning Date: 11-12-2024
Revenue: $3,090,161 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 565.58%

GOVX Daily Stock ML Predictions

Share on Social Networks: